Different types of mAb in clinical use
| Name of monoclonal . | Site of action . | Route of administration . | Clinical trial results* . | In clinical use (outside of clinical trials) . | Viral resistance detected . | Competent authority approval . |
|---|---|---|---|---|---|---|
| Bamlanivimab | Blocks binding of SARS-CoV-2 to the ACE2 receptor by targeting the RBD on the spike protein of SARS-CoV-2 | IV | Yes | Previously—FDA EUA revoked April 2021 | Yes Marked—gamma (P.1) and beta (B.1.351) VoCs Modest—delta (B.1.617.2) VoC | EUA (now revoked in United States) |
| Bamlanivimab plus etesevimab | Blocks binding of SARS-CoV-2 to the ACE2 receptor by targeting different but overlapping epitopes on the spike protein RBD of SARS-CoV-2 | IV | Yes | Yes—use paused in United States | Yes Marked—gamma (P.1) and beta (B.1.351) VoC Modest—Delta (B.1.617.2) VoC | EUA† |
| Casirivimab plus imdevimab | Blocks binding of SARS-CoV-2 to the ACE2 receptor by targeting different epitopes on the spike protein RBD of SARS-CoV-2 (do not overlap) | IV or S/C | Yes | Yes | Yes—only to casirivimab Marked—beta (B.1.351) VoC | Yes—MHRA and Japanese regulatory agency† |
| Sotrovimab | Blocks binding of SARS-CoV-2 to the ACE2 receptor by targeting an epitope on the RBD of the spike protein that is conserved between SARS-CoV and SARS-CoV-2 | IV, trialing IM | Yes | Yes | No | EUA† |
| Regdanvimab | Blocks binding of SARS-CoV-2 to the ACE2 receptor by targeting an epitope on the RBD of the spike protein of SARS-CoV-2 | IV | Yes | Yes | Yes Marked—beta (B.1.351) VoC | EUA‡ |
| Name of monoclonal . | Site of action . | Route of administration . | Clinical trial results* . | In clinical use (outside of clinical trials) . | Viral resistance detected . | Competent authority approval . |
|---|---|---|---|---|---|---|
| Bamlanivimab | Blocks binding of SARS-CoV-2 to the ACE2 receptor by targeting the RBD on the spike protein of SARS-CoV-2 | IV | Yes | Previously—FDA EUA revoked April 2021 | Yes Marked—gamma (P.1) and beta (B.1.351) VoCs Modest—delta (B.1.617.2) VoC | EUA (now revoked in United States) |
| Bamlanivimab plus etesevimab | Blocks binding of SARS-CoV-2 to the ACE2 receptor by targeting different but overlapping epitopes on the spike protein RBD of SARS-CoV-2 | IV | Yes | Yes—use paused in United States | Yes Marked—gamma (P.1) and beta (B.1.351) VoC Modest—Delta (B.1.617.2) VoC | EUA† |
| Casirivimab plus imdevimab | Blocks binding of SARS-CoV-2 to the ACE2 receptor by targeting different epitopes on the spike protein RBD of SARS-CoV-2 (do not overlap) | IV or S/C | Yes | Yes | Yes—only to casirivimab Marked—beta (B.1.351) VoC | Yes—MHRA and Japanese regulatory agency† |
| Sotrovimab | Blocks binding of SARS-CoV-2 to the ACE2 receptor by targeting an epitope on the RBD of the spike protein that is conserved between SARS-CoV and SARS-CoV-2 | IV, trialing IM | Yes | Yes | No | EUA† |
| Regdanvimab | Blocks binding of SARS-CoV-2 to the ACE2 receptor by targeting an epitope on the RBD of the spike protein of SARS-CoV-2 | IV | Yes | Yes | Yes Marked—beta (B.1.351) VoC | EUA‡ |
Results available in Table 2 for all-cause mortality and need for hospitalization (by day 30) in Table 3 for outpatients.
EUA in the United States as well as other countries. In the United States, the indication is for mild or moderate COVID-19 not requiring oxygen therapy.
EUA in South Korea and Indonesia, but indications for use differ.
FDA, Food and Drug Administration (United States); IM, intramuscular; IV, intravenous; MHRA, Medicines and Healthcare products Regulatory Agency (United Kingdom); RBD, receptor-binding domain; S/C, subcutaneous; VoC, variant of concern.